HomeCompareDRFS vs ABBV

DRFS vs ABBV: Dividend Comparison 2026

DRFS yields 4866.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRFS wins by $47809756485645.33M in total portfolio value
10 years
DRFS
DRFS
● Live price
4866.18%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47809756485645.43M
Annual income
$45,952,142,927,845,920,000.00
Full DRFS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DRFS vs ABBV

📍 DRFS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRFSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRFS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRFS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRFS
Annual income on $10K today (after 15% tax)
$413,625.30/yr
After 10yr DRIP, annual income (after tax)
$39,059,321,488,669,024,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DRFS beats the other by $39,059,321,488,669,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRFS + ABBV for your $10,000?

DRFS: 50%ABBV: 50%
100% ABBV50/50100% DRFS
Portfolio after 10yr
$23904878242822.76M
Annual income
$22,976,071,463,922,970,000.00/yr
Blended yield
96.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DRFS
No analyst data
Altman Z
-275.9
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRFS buys
0
ABBV buys
0
No recent congressional trades found for DRFS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRFSABBV
Forward yield4866.18%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$47809756485645.43M$102.3K
Annual income after 10y$45,952,142,927,845,920,000.00$24,771.77
Total dividends collected$47683959808625.34M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DRFS vs ABBV ($10,000, DRIP)

YearDRFS PortfolioDRFS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$497,318$486,618.00$11,550$430.00+$485.8KDRFS
2$23,149,317$22,617,186.48$13,472$627.96+$23.14MDRFS
3$1,008,687,520$983,917,750.67$15,906$926.08+$1008.67MDRFS
4$41,146,910,278$40,067,614,632.00$19,071$1,382.55+$41146.89MDRFS
5$1,571,559,108,431$1,527,531,914,433.18$23,302$2,095.81+$1571559.09MDRFS
6$56,207,112,019,874$54,525,543,773,853.61$29,150$3,237.93+$56207111.99MDRFS
7$1,882,680,394,174,010$1,822,538,784,312,744.20$37,536$5,121.41+$1882680394.14MDRFS
8$59,067,447,560,600,470$57,052,979,538,834,290.00$50,079$8,338.38+$59067447560.55MDRFS
9$1,736,087,437,195,800,600$1,672,885,268,305,958,000.00$69,753$14,065.80+$1736087437195.73MDRFS
10$47,809,756,485,645,430,000$45,952,142,927,845,920,000.00$102,337$24,771.77+$47809756485645.33MDRFS

DRFS vs ABBV: Complete Analysis 2026

DRFSStock

Dr. Foods, Inc. imports, resells, develops, and manufactures various food products. The company was incorporated in 2021 and is based in Tokyo, Japan.

Full DRFS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DRFS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRFS vs SCHDDRFS vs JEPIDRFS vs ODRFS vs KODRFS vs MAINDRFS vs JNJDRFS vs MRKDRFS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.